Dental Beauty Partners (“DBP”) Has Recently Partnered With Kiss Dental, a Leading UK Dental Group Based in Manchester, to Support its Rapid Growth Plans
Kiss Dental is a leading cosmetic dental group in the Northwest of England, which currently has three dental practices. Under the supervision of Dr Kailesh Solanki, CEO of Kiss Dental, they provide the highest standards in dentistry and facial aesthetics. Kiss Dental’s attention to detail and experience in cosmetic dentistry, as well as choosing a dedicated, multidisciplinary team to work with means they provide incredible results for every one of their patients.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220331005104/en/
DBP is a multi-award-winning group providing a range of both NHS and multi-disciplinary private dental services through a partnership model. Since 2019, the founders have expanded DBP from a single practice to over 24 partner-led practices around London. They have built a successful reputation for revamping existing dental practices by attracting the best-in-class clinicians, implementing quality measures and delivering the highest clinical standards, while investing in state-of-the-art facilities and developing a digital patient journey. DBP prides itself in its strong focus on the personal and professional development of its personnel via providing world class mentoring, courses and personal development for all members of the team.
Dr. Kailesh Solanki, comments:
“Dental Beauty Partners has been successfully operating a rapidly growing partner led model for several years. I was very impressed by the experience and knowledge of the management team and DBP’s focus on quality and best-in-class patient care. DBP’s significant investment in their central team, its industry leading management systems and its significant resources will help us accelerate our ambitious growth plans.”
Dev Patel, CEO of DBP, comments:
“We have been impressed by the significant organic growth of Kiss Dental driven by Kailesh and the nationally recognised Kiss Dental team, which thrives on similar values to DBP – best-in-class patient care and a strong focus on digital technology. We are looking forward to supporting Kiss Dental in its next phase of development and welcome all its team members to the DBP family.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
For further information, please contact:
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
University of Nebraska Medical Center and ANANDA Scientific announce FDA approval of the IND for a Clinical Trial exploring Treatment for Post-Traumatic Stress Disorder (PTSD)17.5.2022 14:05:00 EEST | Press release
The University of Nebraska Medical Center (UNMC) and ANANDA Scientific Inc announce a collaboration in a new clinical trial investigating treatment for adults with Post-Traumatic Stress Disorder (PTSD). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005065/en/ (Photo: Business Wire) The trial is being led by principal investigator Mathew Rizzo, M.D., the Reynolds Professor and chair of the UNMC Department of Neurological Sciences and Chief Physician for neurological services at Nebraska Medicine. The study will evaluate the effectiveness of Nantheia™ ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary delivery technology. An investigational new drug (IND) application for the trial has been approved by the U.S. Food and Drug Administration (FDA). (Clinical Trials.gov Identifier NCT05269459) “This is our second clinical trial targeting PTSD. We are excited that UNMC’s research team has partnered with
Trilio Announces Technical Preview of ‘Continuous Restore,’ Delivering Cloud-Native Application Portability and Recoverability in Seconds Across Disparate Infrastructure17.5.2022 14:05:00 EEST | Press release
KUBECON + CLOUDNATIVECON EUROPE— Trilio, a leading provider of cloud-native data protection, today announced a technical preview of a new “Continuous Restore” capability that is being showcased to the cloud-native community at the KubeCon + CloudNativeCon Europe conference. Continuous Restore offers faster levels of replication, restoration and migration of data and metadata from any storage or cloud platform to another, dramatically improving recovery times for cloud-native applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005514/en/ New capability unlocks data gravity and frees data-driven organizations to quickly replicate production-grade Cloud-Native applications to any cloud in seconds. (Graphic: Business Wire) Entirely storage-, cloud- and distribution-agnostic, Trilio’s “Continuous Restore” capability will enable users to continuously stage data at multiple and heterogeneous clouds. This means that a
Forge Biologics Forms Independent Scientific and Manufacturing Advisory Board with Panel of Gene Therapy Leaders17.5.2022 14:00:00 EEST | Press release
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today the formation of an independent board of preeminent experts, a Scientific and Manufacturing Advisory Board (SMAB), to advise the Company on its gene therapy manufacturing offerings and therapeutics pipeline development. The board will serve the traditional functions of a scientific advisory board, with a distinct and strategic emphasis on manufacturing advancements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005561/en/ Credit: Forge Biologics “We are thrilled and privileged to have gathered such a renowned group of experts in gene therapy development and manufacturing to work with us to us deliver quality products to our clients, especially as we accelerate AAV production with our new 5,000L bioreactor,” said Timothy J. Miller, Ph.D., CEO, President, and Co-Founder of Forge Biologics. “The board’s guidance w
Philip Morris International Releases 2021 Integrated Report, Introducing New Sustainability Strategy and Sustainability Index17.5.2022 13:00:00 EEST | Press release
Today, Philip Morris International Inc. (PMI) (NYSE: PM) released its third annual Integrated Report, which includes an updated Statement of Purpose, a new environmental, social, and governance (ESG) framework, as well as detailed information about PMI’s strategic vision, performance, governance, and value creation model. The content was informed by a formal sustainability materiality assessment conducted in 2021. “Sustainability and business performance are fully interrelated and mutually reinforcing. Our actions—grounded in data, science, and facts—speak louder than words. PMI is committed to serving as an agent of change and advocate of positive values. We understand that our business must become a provider of effective alternatives to continued smoking for adult smokers who don’t quit. To achieve this, we are positioning ourselves at the forefront of consumer-centricity, technology, science, and innovation. With an eye to the long term, we are also expanding our business into areas
IHS Holding Limited Reports First Quarter 2022 Financial Results17.5.2022 13:00:00 EEST | Press release
IHS Holding Limited (NYSE: IHS) (“IHS Towers” or the “Company”), one of the largest independent owners, operators and developers of shared communications infrastructure in the world by tower count, today reported financial results for the first quarter ended March 31, 2022. Sam Darwish, IHS Towers Chairman and Chief Executive Officer, stated, “We had another strong quarter, with Revenue, Adjusted EBITDA, and RLFCF all above our own internal expectations, as well as consensus estimates, and we are now tracking towards the higher end of our initial 2022 revenue and adjusted EBITDA guidance, excluding the benefit from adding in our pending deal in South Africa that we expect to close imminently. Including the approximately 5,700 towers subject to the imminent completion of our pending deal in South Africa, IHS will own nearly 39,000 towers across 11 countries, making us the 3rd largest independent multinational tower company by tower count. This geographic scale helps diversify our revenu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom